James Edeerfield Capital Lp... Net Worth

Insiders trading at Dynavax Technologies

Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog... и James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.

What does Dynavax Technologies do?

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.

Dynavax Technologies executives and stock owners

Dynavax Technologies executives and other stock owners filed with the SEC include:

• Ryan Spencer,
  CEO & Director
• David F. Novack,
  Pres & COO
• Dr. Robert Janssen,
  Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs
• Michael S. Ostrach,
  Advisor
• John Slebir,
  Sr. VP & Gen. Counsel
• Nicole Arndt,
  Sr. Mang. of Investor Relations
• Meg Smith,
  VP Sales & Operations
• Steven N. Gersten,
  Chief Ethics & Compliance Officer, Sr. VP, Gen. Counsel and Sec.
• Heather Rowe,
  VP of Investor Relations & Corp. Communications
• Jeff P. Coon,
  Sr. VP of HR & Admin.
• Justin Burgess,
  Principal Accounting Officer & Controller
• Kelly MacDonald,
  Sr. VP & CFO
• Laura Brege,
  Director
• Eddie Gray,
  CEO and Director
• Arnold L Oronsky,
  Director
• Stanley A Plotkin,
  Director
• Daniel L Kisner,
  
• Dennis Carson,
  Director
• Natale S Ricciardi,
  Director
• David Louis Johnson,
  Vice President
• Michael S Ostrach,
  Senior Vice President
• Elaine D Sun,
  
• Francis Cano,
  
• Peter R. Paradiso,
  
• Peggy V Phillips,
  
• Brent Mac Gregor,
  
• Julia Marie Eastland,
  
• Scott Dunseth Myers,
  
• Partners L P/Ilbiotechnolog...,
  
• Nest Gary A Van,
  Vice President
• Dino Dina,
  President and CEO
• Denise Gilbert,
  Director
• Martin E Sanders,
  EVP, Chief Development Officer
• James Edeerfield Capital Lp...,
  
• Partners L P/Ilbiotechnolog...,
  
• James Edeerfield Capital Lp...,
  
• James Edeerfield Capital Lp...,
  
• Deborah A Smeltzer,
  VP Operations & CFO
• Timothy G Henn,
  Vice President
• Zbigniew Janowicz,
  Director
• Daniel Janney,
  Director
• Stephen F Tuck,
  Vice President
• Nancy L Buc,
  Director
• J Tyler Martin,
  VP Clinical Development & CMO
• Christine R Larson,
  VP and Chief Financial Officer
• Capital Partners Lpsymphony...,
  
• Jennifer Lew,
  VP, Finance & PAO
• Mark Kessel,
  Director
• David M Lawrence,
  Director
• Daniel J Levitt,
  VP and Chief Medical Officer
• James Edeerfield Capital Lp...,
  
• Louis C Bock,
  Director
• Jan Leschly,
  Director
• James E Flynn,
  10% owner
• Danielalta California Partn...,
  
• Robert Coffman,
  VP & Chief Scientific Officer
• David F Novack,
  President & COO
• Ryan Spencer,
  CEO and Director
• Robert Janssen,
  SVP and CMO
• Kelly Mac Donald,
  SVP and CFO
• Justin Burgess,
  VP Finance & CAO
• Andrew A. F. Hack,